Abiopharma

New Form SCHEDULE 13G - Alaunos Therapeutics, Inc. Filed: 2025-09-04 AccNo: 0001213900-25-084258 Size: 8 KB

New Form 8-K - Zura Bio Ltd Filed: 2025-09-04 AccNo: 0001104659-25-087286 Size: 19 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Immunic to Participate in Investor and Scientific Conferences in September

New Form 6-K - ALTERITY THERAPEUTICS LTD Filed: 2025-09-04 AccNo: 0001213900-25-084256 Size: 45 KB

New Form EFFECT - Gryphon Digital Mining, Inc. Filed: 2025-09-03 AccNo: 9999999995-25-002822 Size: 1 KB

New Form FWP - BRUKER CORP Filed: 2025-09-04 AccNo: 0001140361-25-033880 Size: 89 KB

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, andTrodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

General Announcement: INTENTION TO DEAL DURING CLOSED PERIOD

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

FDA approve RISPERIDONE

FDA approve TOPIRAMATE

FDA approve VENLAFAXINE HYDROCHLORIDE

FDA approve RISPERIDONE